Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical sildenafil gel for Raynaud's phenomenon attacks in systemic sclerosis
IRCT20240203060886N1Phase 3Completed
- Sponsor
- Shahrekord University of Medical Sciences
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Raynaud disease and systemic sclerosis (SSc) comparing Topical sildenafil 1% gel with Placebo gel (2 arms). Primary endpoints: Pain intensity, Quality of life and 3 more. Started Mar 2024; status: completed.
02
Drugs
sildenafil
03
Conditions
Raynaud diseasesystemic sclerosis (SSc)
Beyond the preview
Go deeper on IRCT20240203060886N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240203060886N1.